Indication
For treatment of severe and moderately severe haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.
Medicine details
- Medicine name:
- etranacogene dezaparvovec (Hemgenix)
- SMC ID:
- SMC2649
- Pharmaceutical company
- CSL Behring
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- 12 August 2024
- SMC meeting date:
- 02 July 2024
- Patient group submission deadline:
- 07 May 2024